Rating of The Day: Is Maxim Group Positive On SciClone Pharmaceuticals (NASDAQ:SCLN)?

November 29, 2016 - By Marguerite Chambers

Rating of The Day: Is Maxim Group Positive On SciClone Pharmaceuticals (NASDAQ:SCLN)?

How Maxim Group Rates SciClone Pharmaceuticals (NASDAQ:SCLN)

Investment firm Maxim Group has initiated coverage on SciClone Pharmaceuticals (NASDAQ:SCLN)‘s stock, rating it “Buy”. This was made public in an analyst report on 29 November.

About 308,880 shares traded hands. SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) has declined 22.11% since April 26, 2016 and is downtrending. It has underperformed by 27.37% the S&P500.

Analysts await SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) to report earnings on March, 9.

Insitutional Activity: The institutional sentiment increased to 1.34 in Q2 2016. Its up 0.16, from 1.18 in 2016Q1. The ratio increased, as 26 funds sold all SciClone Pharmaceuticals, Inc. shares owned while 41 reduced positions. 32 funds bought stakes while 47 increased positions. They now own 38.22 million shares or 3.91% more from 36.79 million shares in 2016Q1.

Geode Capital Management Limited Liability Company, a Massachusetts-based fund reported 346,098 shares. Blackrock Japan reported 1,881 shares or 0% of all its holdings. Gsa Cap Ltd Liability Partnership last reported 0.15% of its portfolio in the stock. D E Shaw Company Inc owns 459,419 shares or 0.01% of their US portfolio. Sensato Limited Liability owns 1.12 million shares or 2.35% of their US portfolio. State Board Of Administration Of Florida Retirement Systems last reported 121,705 shares in the company. Clarivest Asset Mgmt Limited Liability Corporation accumulated 0.06% or 159,545 shares. Alps Advisors Inc reported 113,701 shares or 0.01% of all its holdings. Jpmorgan Chase And Company has 0% invested in the company for 1,576 shares. Hutchin Hill Capital Ltd Partnership has invested 0.04% of its portfolio in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). Aqr Capital Mgmt Limited Liability has 0.01% invested in the company for 560,973 shares. Eqis Capital Mngmt Inc owns 25,359 shares or 0.02% of their US portfolio. Manufacturers Life Insur The holds 0% of its portfolio in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) for 34,479 shares. Goldman Sachs Group accumulated 296,789 shares or 0% of the stock. Pnc Services Group has 328 shares for 0% of their US portfolio.

Insider Transactions: Since August 12, 2016, the stock had 0 insider purchases, and 14 selling transactions for $11.13 million net activity. The insider Cheung Wilson Wai-Shun sold $82,837. Shares for $1.24 million were sold by Hawkins Richard J on Friday, August 12. The insider Zhao Hong sold 40,500 shares worth $421,605. Blobel Friedhelm also sold $5.02M worth of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) on Wednesday, August 17. On Friday, August 12 Meng Chuncai sold $323,574 worth of the stock or 31,083 shares. The insider CHANG NANCY T sold 25,040 shares worth $257,896. 48,667 shares with value of $506,623 were sold by King Robert on Friday, August 12.

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The company has a market cap of $524.58 million. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. It has a 13.66 P/E ratio. The Firm operates in two divisions: China and the Rest of the World, including its activities in the United States and Hong Kong.

According to Zacks Investment Research, “Sciclone Pharmaceuticals, Inc. develops and commercializes novel medicines for treating a broad range of the world’s most serious diseases. They have focused their current product development and commercial activities on the following diseases: hepatitis C, hepatocellular carcinoma, malignant melanoma, hepatitis B, HIV, drug-resistant tuberculosis, cystic fibrosis and others.”

SCLN Company Profile

SciClone Pharmaceuticals, Inc. (SciClone), incorporated on June 26, 2003, is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Firm operates in two divisions: China and the Rest of the World, including its activities in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets approximately seven partnered and in-licensed products in China. The Firm sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

More recent SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on October 28, 2009. Also Prnewswire.com published the news titled: “SciClone Pharmaceuticals To Report Third Quarter 2016 Financial Results On …” on October 25, 2016. Quotes.Wsj.com‘s news article titled: “DOW JONES, A NEWS CORP COMPANY” with publication date: February 12, 2011 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>